Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | MAOA | P21397 | 3/20 | 0.68 |
| ▸ | CTSL | P07711 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenylthiosemicarbazone SCHEMBL674761 | 0.85 | KDM4E (0.81) | KDM4EMAOALMNAHTTPOLB | |
| Phenylthiosemicarbazone SCHEMBL674762 | 0.85 | KDM4E (0.81) | KDM4EMAOALMNAHTTPOLB | |
| Phenylthiosemicarbazone SCHEMBL27878322 | 0.83 | KDM4E (0.78) | KDM4EMAOALMNAHTTPOLB | |
| SCHEMBL4335814 | 0.83 | MAOA (0.58) | KDM4EMAOALMNAHTTALDH1A1 | |
| SCHEMBL4335816 | 0.83 | MAOA (0.58) | KDM4EMAOALMNAHTTALDH1A1 | |
| SCHEMBL28868030 | 0.83 | KDM4E (1.00) | KDM4EMAOALMNAPOLBALDH1A1 | |
| SCHEMBL4262088 | 0.82 | KDM4E (0.76) | KDM4EMAOALMNAHTTPOLB | |
| SCHEMBL14497969 | 0.82 | KDM4E (0.76) | KDM4EMAOALMNAHTTPOLB | |
| SCHEMBL4262083 | 0.82 | KDM4E (0.76) | KDM4EMAOALMNAHTTPOLB | |
| SCHEMBL4331982 | 0.81 | MAPT (0.67) | KDM4ELMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090285849-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2009-11-19 | — | — | US | disclosed |
| US-7521062-B2 | Thiosemicarbazones as anti-virals and immunopotentiators | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090285849-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | MAVS, IRF3, HAVCR2 | KDM4E 3010/4885MAOA 4418/4885CTSL 2815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.